Ipsen acquired ImCheck Therapeutics, a Marseille based company with a unique immune-oncology antibody, for $350M last year. ImCheck's former CEO, Pierre d'Epenoux tells the story behind it
- Jun 4
- 1 min read
He discusses the idea behind the company and the buyout, and how ImCheck was a product of the broader French biotech ecosystem.










.png)